The individual analysis of the immune checkpoints LAG-3, TIM-3 and PD-1 on NK cells showed no statistically significant differences in the expression of LAG-3 (Fig. 2a) between AML patients and healthy donors (61.75 ± 10.02 and 59.83 ± 13.66 respectively). This evidence concerns the gene HAVCR2 and acute myeloid leukemia.